Search

Displaying results 2901 - 2910 of 8697 in total
  1. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 1

    go.drugbank.com/bio_entities/BE0010562
    TargetHumans

    Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). … Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response.

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 1Synonyms: Leukocyte immunoglobulin-like receptor 1, Monocyte/macrophage immunoglobulin-like receptor 7
  2. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 4

    go.drugbank.com/bio_entities/BE0017129
    TargetHumans

    Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213). … Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462). Receptor for FN1 (PubMed:34089617).

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 4Synonyms: Monocyte inhibitory receptor HM18, Leukocyte immunoglobulin-like receptor 5
  3. Target

    Nuclear receptor subfamily 1 group I member 3

    go.drugbank.com/bio_entities/BE0003848
    TargetHumans

    Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes.

    Polypeptides: Nuclear receptor subfamily 1 group I member 3Synonyms: Orphan nuclear receptor MB67, Constitutive androstane receptor
  4. Drug

    Carbocisteine

    go.drugbank.com/drugs/DB04339
    ApprovedInvestigational

    [A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America. … [L32383] Several licenses for this drug were withdrawn following serious and fatal paradoxical effects after carbocisteine therapy in children; respiratory dress, dyspnea, and cough aggravation were

  5. Drug

    Lisavanbulin

    go.drugbank.com/drugs/DB15224
    Investigational

    Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

  6. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    It may have some anticonvulsant properties.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    It is susceptible to gastric juice and penicillinase and may damage platelet function.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. … It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  9. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  10. Drug

    Isoetharine

    go.drugbank.com/drugs/DB00221
    Approved

    Isoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma.[A330]

    Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway Diseases